Product Pipeline

 
Phase I
Phase II
Phase III
Highlights

RCH-01

Pattern Baldness
Shiseido-Funded Japanese Clinical Research Study

RCH-01 is a proprietary autologous cell therapy being developed to treat pattern baldness.*

*This product is currently in clinical testing and not yet commercially available.

Details

RCS-01

Aging & Sun-Damaged Skin
Phase I Complete

RCS-01 is a proprietary autologous cell therapy being developed to rejuvenate aging or UV-damaged skin.*

*This product is currently in clinical testing and not yet commercially available.

Details

RCT-01

Chronic Achilles Tendinopathy
Phase I Complete

Product Description: RCT-01 is a proprietary autologous cell therapy being developed to treat chronically damaged tendons. *

*This product is currently in clinical testing and not yet commercially available.

Details
 
Design
Prototype & Test
Market Launch
Highlights

RCI-02

Dermal Injector Device
Pre-Commercial Production and Testing

RCI-02 is a next-generation dermal injector designed to provide an improved level of control and precision for intradermal (dermis) and subcutaneous (extracellular matrix & fat) injections. *

*This product is currently in prototype development and testing and not yet commercially available.

Details